Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by pericles1on Oct 15, 2010 11:14am

437 Views

Post# 17569043

RE: RE: RE: RE: From the Yahoo board.

I reviewed that meeting from post 27948362 that rjc 2827 posted and Brad was on a roll with optimism. He also said we should run the phase III A in about 8 months, that will not happen in my opinion, make it closer to a year. He is already admitting it when he said recently that the first phase should finish next summer and then the start the B phase.

Bullboard Posts

Sony’s Alpha 1 II: A new professional photography standard?